TPP Raises Concerns About Drug Patents, Pricing and Availability

The Trans-Pacific Partnership could affect pharmaceutical pricing around the globe if ratified and implemented by the dozen signatory countries, and is a big concern to physician advocates on the front lines of ensuring advanced medicines are available and affordable in developing countries. Learn more here. (Source: Jaclyn Schiff, Modern Healthcare, 6/4/16)

You might also be interested in:

eDossier System to Offer hēRo3 Model Integration November 8, 2018
Column Proposes ‘One-and-Done’ Solution for Drug Patents February 12, 2019
Pharmerit Expands Market Access Support in Asia January 17, 2019
New Non-Profit Association Launches Free Guideline… January 16, 2019
CVS Caremark’s Foray into Cost-Effectiveness Analysis… September 25, 2018
Documentary Spotlights Drug Pricing in U.S. December 17, 2018
Gottlieb’s Statement on Administration Funding Request February 19, 2018